Business
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.
About this update from Protalix Biotherapeutics, Inc. (de)
[{"type":"text","content":"Company to host conference call and webcast today at 8:00 a.m. EST","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.","length":433,"tagName":"p"},{"type":"image","alt":"Protalix Biotherapeutics Logo (PRNewsfoto/Protalix Biotherapeutics Inc)","displaySize":"","headline":null,"caption":"Protalix Biotherapeutics Logo (PRNewsfoto/Protalix Biotherapeutics Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqTp0X7VmxnrsXQUFDueUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","width":400,"height":121}},"href":"https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"\"We are pleased to report total revenues of $43.6 million for the first nine months of 2025, an increase of 24%, compared to the same period in 2024. Our total revenues for the third quarter were $17.9 million which reflects a decrease of 1%, compared to revenues for the same period of 2024,\" said Dror Bashan, Protalix's President and Chief Executive Officer. \"We recognize revenues from sales of our products to Chiesi, Pfizer, and Fiocruz in Brazil, and their purchases vary from quarter to quarter as they control their own inventories. Overall, these revenues reflect the continued commercial success of our enzyme replacement therapies and provide a strong foundation to support our research and development efforts.\"","length":724,"tagName":"p"},{"type":"text","content":"\"We are particularly excited about PRX-115, our recombinant PEGylated uricase candidate under development for the treatment of uncontrolled gout, which we believe has the potential to be a differentiating treatment for uncontr...